Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 9, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012 at 10:00 a.m. (ET) in Boston. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com.

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 2, 2012– AVEO Oncology (NASDAQ: AVEO) today reported consolidated financial results for the second quarter of 2012, and highlighted recent developments and key second quarter accomplishments. “The last six months have been very productive for AVEO Oncology, as highlighted by the presentation of the positive results from the TIVO-1 trial of tivozanib in

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 26, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s second quarter ended June 30, 2012 will be released before the market opens on Thursday, August 2, 2012. The AVEO management team will host a conference call discussing the company’s financial results and key recent accomplishments on Thursday, August 2,

Download PDF Study designed to build upon safety profile demonstrated in TIVO-1 study CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Jun. 4, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS (TivozAnib Use veRsUs Sutent in advanced renal cell carcinoma (RCC): Patient Preference), to establish additional data regarding the investigational drug tivozanib when used as

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 30, 2012– AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.m. (CT) to review the Phase 3 TIVO-1 data that will be presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). The call can be accessed by dialing 1-800-215-2410

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 29, 2012– AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay

Download PDF AV-203 is the Third AVEO Molecule to Enter Clinic CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 23, 2012– AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors. AV-203 is a monoclonal antibody that selectively targets the receptor ERBB3,

Download PDF – Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment – – First Pivotal Trial vs. Active Targeted Agent in First-Line Advanced RCC – – Study Results Demonstrate Unique Combination of Superior PFS and Favorable Tolerability – CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–May. 16, 2012– AVEO Oncology (NASDAQ:AVEO) and Astellas